medwireNews

A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

The addition of abatacept to standard therapy does not increase the rate of complete renal response among patients with lupus nephritis, phase III study findings show.

Patients with juvenile idiopathic arthritis who are treated with etanercept do not have a higher risk for developing uveitis than those given methotrexate, results of a UK cohort study suggest.

Adding atezolizumab to bevacizumab plus chemotherapy significantly delays disease progression and death among chemotherapy-naïve patients with metastatic nonsquamous non-small-cell lung cancer, phase III study data show.

Belimumab, a B-lymphocyte stimulator specific inhibitor used for the treatment of systemic lupus erythematosus, has a stable safety profile over 8 years of follow-up, with no new safety signals observed, report researchers.